Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOLIRIS vs BLENREP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.
Paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis,Atypical hemolytic uremic syndrome (a HUS) to inhibit complement-mediated thrombotic microangiopathy,Generalized myasthenia gravis (g MG) in adult patients who are anti-acetylcholine receptor antibody-positive,Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 antibody-positive
FDA-approved for relapsed or refractory multiple myeloma in adults who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (a HUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.
2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Terminal elimination half-life: approximately 11.3 ± 3.4 days (range 8–18 days) following biweekly dosing. This supports a dosing interval of every 2 weeks for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
The terminal elimination half-life of belantamab mafodotin is approximately 12 days (range 9-19 days). This supports a dosing interval of every 3 weeks, allowing for drug clearance between cycles while maintaining therapeutic exposure.
Eculizumab is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved.
Belantamab mafodotin is likely metabolized via proteolytic degradation into small peptides and amino acids; MMAF is a substrate of CYP3A and P-glycoprotein, but the contribution of CYP3A to clearance is limited.
Eculizumab is not metabolized by cytochrome P450 enzymes; it is degraded via general protein catabolism. Clearance is primarily through the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). No biliary or fecal excretion data are available in humans.
Blenrep (belantamab mafodotin) is eliminated primarily via catabolism, with no significant renal or biliary excretion of intact drug. The small molecule toxin, monomethyl auristatin F (MMAF), is excreted via feces (72%) and urine (28%) after release from the antibody conjugate.
Eculizumab is a recombinant humanized monoclonal antibody; it does not bind to serum proteins significantly. Protein binding is negligible (approximately 0%), as it is a large protein molecule.
Belantamab mafodotin is highly protein-bound (>99%) to plasma proteins, predominantly to albumin. The released MMAF is also extensively protein-bound (approximately 90% to albumin).
Volume of distribution at steady state: approximately 7.5 L (0.11 L/kg in a 70 kg adult), indicating distribution primarily within the vascular and interstitial spaces, consistent with limited extravascular distribution of a large monoclonal antibody.
The volume of distribution of belantamab mafodotin is approximately 7.8 L (range 4.5-12.4 L), which is slightly greater than plasma volume, indicating limited extravascular distribution. The Vd is not typically normalized to body weight; however, dosing is weight-based (mg/kg) to account for interpatient variability.
Intravenous administration only; bioavailability is 100% by the intravenous route. No oral or other routes are available.
Blenrep is administered as an intravenous infusion; thus, bioavailability is 100% by the intravenous route. No oral or other routes are approved.
No dose adjustment required based on GFR. Eculizumab is not renally cleared.
For moderate renal impairment (e GFR 30-59 m L/min/1.73 m²): reduce dose to 1.9 mg/kg. For severe renal impairment (e GFR 15-29 m L/min/1.73 m²): not recommended. For e GFR <15 m L/min/1.73 m²: contraindicated.
No specific guidelines for hepatic impairment; likely no adjustment needed as metabolism is not hepatic.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 1.9 mg/kg. Child-Pugh Class C: not recommended.
For a HUS: weight-based: 5 to <10 kg: 300 mg; 10 to <20 kg: 600 mg; 20 to <30 kg: 600 mg; 30 to <40 kg: 900 mg; >=40 kg: 900 mg. Induction: weekly x4, then dose 1 week later, then maintenance every 2 weeks. For PNH: not approved in children <18 years.
Safety and efficacy not established; no specific pediatric dosing guidelines available.
No specific dose adjustment. Monitor for infections, especially meningococcal, as elderly may have increased susceptibility.
No specific dose adjustment recommended based on age alone; monitor renal function and consider dose adjustment per renal impairment guidelines.
SOLIRIS increases the risk of meningococcal infections. Patients must receive meningococcal vaccination at least 2 weeks prior to administration, unless the risks of delaying therapy outweigh the risks of developing a meningococcal infection. Patients should be monitored for early signs of meningococcal infection and evaluated immediately if infection is suspected.
WARNING: OCULAR TOXICITY. Blenrep (belantamab mafodotin) causes severe ocular toxicity, including keratopathy and changes in visual acuity, which may require dose modification or discontinuation. Perform ophthalmic exams prior to each dose. Use only in patients who have received at least 4 prior therapies.
Increased susceptibility to meningococcal infections due to complement inhibition; vaccinate and monitor,Other Neisseria species and encapsulated bacteria infections (e.g., Streptococcus pneumoniae, Haemophilus influenzae type b); consider vaccination,Infusion reactions: including anaphylaxis and hypersensitivity; discontinue if severe,Monitoring for hemolysis in PNH patients: discontinue if evidence of severe hemolysis,Monitoring for thrombotic microangiopathy (TMA) in a HUS patients: discontinue if TMA complications occur
Ocular toxicity (keratopathy, visual acuity changes),Thrombocytopenia,Infusion-related reactions,Hepatotoxicity (increased transaminases),Embryo-fetal toxicity
Unresolved serious Neisseria meningitidis infection,Patients not currently vaccinated against Neisseria meningitidis (unless delays in therapy outweigh risks),Known hypersensitivity to eculizumab or any of its excipients
None known
No clinically significant food interactions reported; administer intravenously over 35 minutes.
No specific food interactions known. Maintain adequate hydration.
First trimester: No adequate human data; animal studies show no evidence of teratogenicity. Second and third trimesters: Both mother and fetus may have increased risk of infections due to complement inhibition; monitor for meningococcal and other infections. No known structural teratogenicity.
FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fetal toxicity and teratogenicity due to the microtubule inhibitor; avoid use unless maternal benefit outweighs risk.
No human data; eculizumab is a large monoclonal antibody likely to be present in minimal amounts in breast milk due to molecular size; M/P ratio unknown. Caution advised.
No data on presence in human milk. M/P ratio unknown. Advise to discontinue breastfeeding during treatment and for at least 3 months after last dose due to potential for severe adverse reactions in breastfed infants.
No formal studies; pharmacokinetics may be altered due to increased plasma volume and renal function; consider monitoring drug levels if available, but no specific dose adjustment recommended.
No specific dose adjustments in pregnancy established. Use is not recommended; if unavoidable, consider dose reduction based on tolerability (e.g., for ocular toxicity). No pharmacokinetic data available to guide adjustments.
Administer meningococcal vaccines at least 2 weeks prior to first dose; vaccinate against Neisseria meningitidis serogroups A, C, Y, W-135 and serogroup B. Monitor for hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) after discontinuation. Do not administer live vaccines. Infusion reactions may occur; premedicate with antihistamines and corticosteroids if needed. Eculizumab increases risk of serious infections, especially encapsulated bacteria. Prescribe prophylactic antibiotics if vaccination cannot be given 2 weeks prior. Monitor LDH, hemoglobin, and reticulocyte count in PNH.
Monitor for ocular toxicity, including keratitis and uveitis; perform ophthalmic exams at baseline and during therapy. Premedicate with corticosteroids and vasoconstrictors to reduce infusion reactions. Blenrep is a BCMA-directed antibody-drug conjugate for relapsed/refractory multiple myeloma. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min).
You must receive meningococcal vaccines at least 2 weeks before starting treatment.,This medication increases your risk of serious infections, especially meningitis.,Report any signs of infection such as fever, headache with stiff neck, or rash immediately.,Do not receive live vaccines while on this medication.,If you stop treatment, your healthcare provider will monitor you for red blood cell breakdown.,Promptly report any bruises, bleeding, or signs of injection site reaction.
Inform your doctor immediately if you experience blurred vision, eye pain, or light sensitivity.,You will need eye exams before and during treatment.,Report any signs of infusion reactions such as chills, fever, or difficulty breathing.,Use effective contraception during treatment and for 4 months after the last dose.,Avoid driving or operating machinery if you have vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOLIRIS vs BLENREP, answered by our medical review team.
SOLIRIS is a Monoclonal Antibody that works by Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.. BLENREP is a Antineoplastic, Monoclonal Antibody that works by Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOLIRIS and BLENREP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOLIRIS is: 600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (a HUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.. The standard adult dose of BLENREP is: 2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOLIRIS and BLENREP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOLIRIS is classified as Category C. First trimester: No adequate human data; animal studies show no evidence of teratogenicity. Second and third trimesters: Both mother and fetus may have increased risk of infections. BLENREP is classified as Category C. FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.